BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lee J, Vali Y, Boursier J, Duffin K, Verheij J, Brosnan MJ, Zwinderman K, Anstee QM, Bossuyt PM, Zafarmand MH. Accuracy of cytokeratin 18 (M30 and M65) in detecting non-alcoholic steatohepatitis and fibrosis: A systematic review and meta-analysis. PLoS One 2020;15:e0238717. [PMID: 32915852 DOI: 10.1371/journal.pone.0238717] [Cited by in Crossref: 13] [Cited by in F6Publishing: 18] [Article Influence: 6.5] [Reference Citation Analysis]
Number Citing Articles
1 Singh Bhangu J, Macher-beer A, Schimek V, Garmroudi B, Tamandl D, Unger LW, Bachleitner-hofmann T, Oehler R. Circulating caspase-cleaved cytokeratin 18 correlates with tumour burden and response to therapy in patients with colorectal cancer liver metastasis. Clinica Chimica Acta 2022. [DOI: 10.1016/j.cca.2022.11.009] [Reference Citation Analysis]
2 Thorhauge KH, Thiele M, Detlefsen S, Rasmussen DN, Johansen S, Madsen BS, Antonsen S, Rasmussen LM, Lindvig KP, Krag A. Serum keratin-18 detects hepatic inflammation and predicts progression in compensated alcohol-associated liver disease. Hepatol Commun 2022. [PMID: 36264145 DOI: 10.1002/hep4.2075] [Reference Citation Analysis]
3 Eguchi A, Iwasa M, Tamai Y, Yamada M, Okuno K, Shigefuku R, Yoshikawa K, Tempaku M, Sakaguchi K, Tanaka H, Sugimoto K, Kobayashi Y, Yamaguchi T, Nakagawa H. The prognostic potential of fragmented CK18 serum levels in HCC patients reflecting disease progression and overall hepatocyte damage. Front Oncol 2022;12:993705. [DOI: 10.3389/fonc.2022.993705] [Reference Citation Analysis]
4 Eguchi A, Iwasa M, Yamada M, Tamai Y, Shigefuku R, Hasegawa H, Hirokawa Y, Hayashi A, Okuno K, Matsushita Y, Nakatsuka T, Enooku K, Sakaguchi K, Kobayashi Y, Yamaguchi T, Watanabe M, Takei Y, Nakagawa H. A new detection system for serum fragmented cytokeratin 18 as a biomarker reflecting histologic activities of human nonalcoholic steatohepatitis. Hepatol Commun 2022. [PMID: 35485207 DOI: 10.1002/hep4.1971] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Yang HC, Xing ZK, Shao H, Tan XW, Wang EQ, Liao Y, Chen HJ, Wu XW, Chen XL, Zhang SJ. The expression of cytokeratin and apoptosis-related molecules in echinococcosis related liver injury. Mol Biochem Parasitol 2022;248:111455. [PMID: 35016896 DOI: 10.1016/j.molbiopara.2022.111455] [Reference Citation Analysis]
6 Cave MC, Pinkston CM, Rai SN, Wahlang B, Pavuk M, Head KZ, Carswell GK, Nelson GM, Klinge CM, Bell DA, Birnbaum LS, Chorley BN. Circulating MicroRNAs, Polychlorinated Biphenyls, and Environmental Liver Disease in the Anniston Community Health Survey. Environ Health Perspect 2022;130:17003. [PMID: 34989596 DOI: 10.1289/EHP9467] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Mcgill MR. Biomarkers of Liver Injury Due to Toxic Agents: Progress, Current Applications, and Emerging Directions. Biomarkers in Toxicology 2022. [DOI: 10.1007/978-3-030-87225-0_14-1] [Reference Citation Analysis]
8 Dorairaj V, Sulaiman SA, Abu N, Abdul Murad NA. Nonalcoholic Fatty Liver Disease (NAFLD): Pathogenesis and Noninvasive Diagnosis. Biomedicines 2021;10:15. [PMID: 35052690 DOI: 10.3390/biomedicines10010015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
9 Gallego-Durán R, Montero-Vallejo R, Maya-Miles D, Lucena A, Martin F, Ampuero J, Romero-Gómez M. Analysis of Common Pathways and Markers From Non-Alcoholic Fatty Liver Disease to Immune-Mediated Diseases. Front Immunol 2021;12:667354. [PMID: 34899679 DOI: 10.3389/fimmu.2021.667354] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
10 Hashim A, Bremner S, Grove JI, Astbury S, Mengozzi M, O'Sullivan M, Macken L, Worthley T, Katarey D, Aithal GP, Verma S. Chronic liver disease in homeless individuals and performance of non-invasive liver fibrosis and injury markers: VALID study. Liver Int 2021. [PMID: 34846794 DOI: 10.1111/liv.15122] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Yamada M, Eguchi A, Okuno K, Sakaguchi K, Yamaguchi T. Development of a highly sensitive chemiluminescent enzyme immunoassay for fragmented cytokeratin 18 using new antibodies. Sci Rep 2021;11:18187. [PMID: 34521905 DOI: 10.1038/s41598-021-97439-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Alqahtani SA, Schattenberg JM. Nonalcoholic fatty liver disease: use of diagnostic biomarkers and modalities in clinical practice. Expert Rev Mol Diagn 2021;:1-14. [PMID: 34346799 DOI: 10.1080/14737159.2021.1964958] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
13 Manco M, Panera N, Crudele A, Braghini MR, Bianchi M, Comparcola D, De Vito R, Maggiore G, Alisi A. Angiopoietin-2 levels correlates with disease activity in children with nonalcoholic fatty liver disease. Pediatr Res 2021. [PMID: 34331020 DOI: 10.1038/s41390-021-01666-5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Van Dijk AM, Vali Y, Mak AL, Lee J, Tushuizen ME, Zafarmand MH, Anstee QM, Brosnan MJ, Nieuwdorp M, Bossuyt PM, Holleboom AG. Systematic Review with Meta-Analyses: Diagnostic Accuracy of FibroMeter Tests in Patients with Non-Alcoholic Fatty Liver Disease. J Clin Med 2021;10:2910. [PMID: 34209858 DOI: 10.3390/jcm10132910] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
15 Vali Y, Leeflang MMG, Bossuyt PMM. Application of weighting methods for presenting risk-of-bias assessments in systematic reviews of diagnostic test accuracy studies. Syst Rev 2021;10:191. [PMID: 34174958 DOI: 10.1186/s13643-021-01744-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Maude H, Sanchez-Cabanillas C, Cebola I. Epigenetics of Hepatic Insulin Resistance. Front Endocrinol (Lausanne) 2021;12:681356. [PMID: 34046015 DOI: 10.3389/fendo.2021.681356] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
17 Notarnicola M, Osella AR, Caruso MG, Pesole PL, Lippolis A, Tutino V, Bonfiglio C, De Nunzio V, Scavo MP, Mirizzi A, Franco I, Lippolis T, D'Alessandro R, Refolo MG, Messa C. Nonalcoholic Fatty Liver Disease: Focus on New Biomarkers and Lifestyle Interventions. Int J Mol Sci 2021;22:3899. [PMID: 33918878 DOI: 10.3390/ijms22083899] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]